Matching geography Reports matching your search in: Join Alert Me now! Receive bi-weekly email alerts on new market research Sign up today!
|
Women's Health: market research reports
Women’s health is a perspective of prevention and treatment that looks at health concerns unique to females. Even though slightly more than half of the US population is female, medical research historically has neglected the health needs of women, other than reproductive issues. Recently there have been major changes in government and private support of women’s health research -- in policies, regulations, and the organization of research efforts. In a recent Institute of Medicine (IOM) report, the Washington DC-based institute found that women’s health research has contributed to significant progress over the past 20 years in lessening the burden of disease and reducing deaths from some conditions for women, while other conditions have seen only moderate change or even little or no change. Gaps remain, both in research areas and in the application of results to benefit women in general and across multiple population groups. Viewing women’s health exclusively as a function of sex differences is too narrow, according to the IOM report. It frames women’s health and well-being as a function only of biological factors and how they differ in men and women, and ignores the role of gender, which is affected by broader social and community factors. The IOM finds that there has been inadequate attention paid to the social and environmental factors that, along with biologic risk factors, influence women’s health. Although progress has been made in identifying behavioral determinants of women’s health, such as smoking, diet, and physical activity, few studies have tested ways to modify these determinants in women or examined the effects of social and community factors in specific groups of women. To advance this area of research, the IOM recommends that the National Institutes of Health (NIH) support research on common determinants and risk factors that underlie multiple diseases. Significant progress has been made in reducing mortality for women from breast cancer, cardiovascular disease and cervical cancer. This can be attributed in part to increased consumer demand and awareness, which has resulted in additional funding and research; improved diagnosis; screening and treatment; and, in the case of cervical cancer, a vaccine.
Women's Health market research reports and industry analysis
Analysis Of Market Of Women Hygiene In Russia
5/5/2013 | published by: Euroresearch & Consulting
... of the market in Russia. The report forms a view with respect to development of the market. This view and forecast can be used in running scenario analysis to build financial models, investment analysis and ...
|
read more...
|
$1,850.00
|
Metastatic Ovarian Cancer – Pipeline Review, H1 2013
4/30/2013 | published by: Global Markets Direct
... therapeutic development for Metastatic Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer. Metastatic Ovarian Cancer ...
|
read more...
|
$2,000.00
|
Emergency Contraception in Latvia
4/24/2013 | published by: Euromonitor International
... of emergency contraception traditionally surge in summertime, particularly in June. Short-term peaks in sales are observed also during other holidays such as Easter and Christmas. Euromonitor International's Emergency Contraception in Latvia report offers a comprehensive ...
|
read more...
|
$900.00
|
Emergency Contraception in Lithuania
4/24/2013 | published by: Euromonitor International
... of products and awareness of them amongst potential customers – to generate sales. From this perspective, the category experienced solid performance. Euromonitor International's Emergency Contraception in Lithuania report offers a comprehensive guide to the size ...
|
read more...
|
$900.00
|
Ovarian Cancer Drug Pipeline Update 2013
4/22/2013 | published by: BioSeeker Group AB
... an important secondary indication for existing and pipeline drugs. There are today 220 companies plus partners developing 306 drugs targeting ovarian cancer in development. In addition, there are 8 suspended drugs and the accumulated number ...
|
read more...
|
$5,621.25
|
Breast Cancer Drug Pipeline Update 2013
4/22/2013 | published by: BioSeeker Group AB
... and metastatic setting, the overall survival remains below five years. There are today 359 companies plus partners developing 497 drugs targeting breast cancer in development. In addition, there are 9 suspended drugs and the accumulated ...
|
read more...
|
$5,621.25
|
Analytical Tool - Breast Cancer
4/22/2013 | published by: BioSeeker Group AB
... map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies ...
|
read more...
|
$11,625.00
|
Post Menopausal Osteoporosis – Pipeline Review, H1 2013
4/17/2013 | published by: Global Markets Direct
... therapeutic development for Post Menopausal Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis. Post Menopausal Osteoporosis ...
|
read more...
|
$2,000.00
|
Uterine Cancer – Pipeline Review, H1 2013
4/17/2013 | published by: Global Markets Direct
... for Uterine Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uterine Cancer. Uterine Cancer - Pipeline Review, Half Year ...
|
read more...
|
$2,000.00
|
Female Hypoactive Sexual Desire Disorder – Pipeline Review, H1 2013
4/17/2013 | published by: Global Markets Direct
... provides information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for ...
|
read more...
|
$2,000.00
|
2013 Analysis of the Pap Smear/HPV Testing Market: US, Europe (France, Germany, Italy, Spain, UK), Japan-- Emerging Opportunities, Country Forecasts, Innovative Technologies, and Competitive Landscape
4/17/2013 | published by: Venture Planning Group
... the disease. During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting ...
|
read more...
|
$4,350.00
|
Ovarian Cancer – Pipeline Review, H1 2013
4/10/2013 | published by: Global Markets Direct
... for Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ovarian Cancer. Ovarian Cancer - Pipeline Review, Half Year ...
|
read more...
|
$2,500.00
|
Breast Cancer – Pipeline Review, H1 2013
4/10/2013 | published by: Global Markets Direct
... for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Breast Cancer. Breast Cancer - Pipeline Review, Half Year ...
|
read more...
|
$2,500.00
|
|
|
$3,995.00
|
Female Sexual Dysfunction – Pipeline Review, H1 2013
3/28/2013 | published by: Global Markets Direct
... therapeutic development for Female Sexual Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Female Sexual Dysfunction. Female Sexual Dysfunction ...
|
read more...
|
$2,000.00
|
Menopausal Disorders – Pipeline Review, H1 2013
3/28/2013 | published by: Global Markets Direct
... for Menopausal Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Menopausal Disorders. Menopausal Disorders - Pipeline Review, Half Year ...
|
read more...
|
$2,000.00
|
Uterine Fibroids – Pipeline Review, H1 2013
3/28/2013 | published by: Global Markets Direct
... for Uterine Fibroids, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uterine Fibroids. Uterine Fibroids - Pipeline Review, Half Year ...
|
read more...
|
$2,000.00
|
Menopausal Hot Flashes – Pipeline Review, H1 2013
3/28/2013 | published by: Global Markets Direct
... therapeutic development for Menopausal Hot Flashes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Menopausal Hot Flashes. Menopausal Hot Flashes ...
|
read more...
|
$2,000.00
|
Vaginal Atrophy (Atrophic Vaginitis) – Pipeline Review, H1 2013
3/28/2013 | published by: Global Markets Direct
... on the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vaginal Atrophy (Atrophic ...
|
read more...
|
$2,000.00
|
Cervical Dysplasia – Pipeline Review, H1 2013
3/28/2013 | published by: Global Markets Direct
... for Cervical Dysplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Dysplasia. Cervical Dysplasia - Pipeline Review, Half Year ...
|
read more...
|
$2,000.00
|
|
|
$5,175.00
|
|
|
$5,175.00
|
Human Papillomavirus Infections – Pipeline Review, H1 2013
3/18/2013 | published by: Global Markets Direct
... development for Human Papillomavirus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections. Human Papillomavirus Infections - ...
|
read more...
|
$2,000.00
|
|
|
$199.00
|
Fallopian Tube Cancer – Pipeline Review, H1 2013
2/28/2013 | published by: Global Markets Direct
... development for Fallopian Tube Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer. Fallopian Tube Cancer - ...
|
read more...
|
$2,000.00
|
< prev 1 2 3 4 5 6 7 8 9 10 next >
|